Ratings Thermo Fisher Scientific Inc. Buenos Aires S.E.

Equities

TMOD

ARBCOM4601F7

End-of-day quote Buenos Aires S.E. Other stock markets 23:00:00 13/04/2023 BST			5-day change	1st Jan Change
27 ^USD	-.--%		-.--%	-.--%

06-03	Thermo Fisher Scientific Introduces Innovative Mass Spectrometer to Advance Clinical Research	CI
06-03	Thermo Fisher Scientific Opens New GMP-Certified Ultra-Cold Facility in the EU to Accelerate Advanced Therapies Development	CI

Strengths

The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
The company returns high margins, thereby supporting business profitability.
The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.
The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
Historically, the company has been releasing figures that are above expectations.

Weaknesses

The group shows a rather high level of debt in proportion to its EBITDA.
With an expected P/E ratio at 35.77 and 30.68 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
The company's "enterprise value to sales" ratio is among the highest in the world.
The company appears highly valued given the size of its balance sheet.
The valuation of the company is particularly high given the cash flows generated by its activity.
The company is not the most generous with respect to shareholders' compensation.
For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
The average consensus view of analysts covering the stock has deteriorated over the past four months.
Over the past twelve months, analysts' consensus has been significantly revised downwards.

Ratings chart - Surperformance

Sector: Advanced Medical Equipment & Technology

	1st Jan change	Capi.	ESG Refinitiv
THERMO FISHER SCIENTIFIC INC.	-.--%	217B	-
DANAHER CORPORATION	+13.66%	194B	B-
INTUITIVE SURGICAL, INC.	+19.93%	143B	B-
BOSTON SCIENTIFIC CORPORATION	+31.05%	111B	A-
SIEMENS HEALTHINEERS AG	+3.08%	64.3B	A-
EDWARDS LIFESCIENCES CORPORATION	+14.76%	52.94B	B+
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.	+2.72%	49.53B	B+
AGILENT TECHNOLOGIES, INC.	-5.74%	38.31B	A
GE HEALTHCARE TECHNOLOGIES INC.	-0.30%	35.22B	-
RESMED, INC.	+22.53%	30.47B	B+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes